Mucosolvan serves to optimize perioperative airway management for NSCLC patients in fast track surgery: a randomized placebo controlled study.
This study is conducted to investigate whether mucosolvan may offer therapy optimization initiatives for airway perioperative management of patients with non-small cell lung cancer (NSCLC) in fast track surgery (FTS). The patients in FTS were treated with and without aerosol (90 mg/day) of mucosolvan in combination of intravenous administration of the agent (180 mg/day) for 8 consecutive days. Postoperative complications and length of time of hospital stay were examined in the patients treated with and without mucosolvan. Prevalence rate for the overall postoperative complication was significantly decreased in the mucosolvan-treated patients as compared to the untreated ones (p < 0.05). In further analysis, an appearance of postoperative pulmonary complication was reduced in the treated patients as well (p < 0.05). There was no statistical difference in a morbidity rate of postoperative cardiac complications between these two groups. Furthermore, treatment with mucosolvan resulted in significantly decreasing length of time of hospital stay as compared to the untreated patients (p < 0.05), indicating that this agent may facilitate early recovery of the patients in FTS after major surgical approaches. Mucosolvan optimizes the perioperative airway management for NSCLC patients in FTS through reducing postoperative complications and shortening time of hospital stay.